Lv51
1040 积分 2024-09-09 加入
CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma
30天前
已完结
Abstract CT159: First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors
5个月前
已关闭
First clinical experience using targeted alpha-emitter therapy with 212Pb-DOTAMTATE (AlphaMedix TM) in patients with SSTR(+) neuroendocrine tumors
5个月前
已关闭
Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients
5个月前
已关闭
皖公网安备34019202002308
